Abemaciclib: Interim Ph III MONARCH 3 data

Interim data from the double-blind, placebo-controlled, international Phase III MONARCH 3 trial in 493 postmenopausal women with hormone receptor-positive, HER2-negative, locoregionally recurrent or metastatic breast cancer showed that twice-daily 150 mg oral abemaciclib plus anastrozole or letrozole met the primary endpoint of improving PFS vs. anastrozole or letrozole alone. Abemaciclib plus anastrozole or letrozole also met the secondary endpoint of improving ORR vs. anastrozole or letrozole alone. Eli Lilly said it plans to submit global regulatory applications based on the MONARCH 3 data in 3Q17...